Companies ArriVent BioPharma, Inc.
ArriVent BioPharma (AVBP): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me ArriVent BioPharma, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $2,406,649FY2024
- $9,374,153FY2025
CEO total pay was $9,374,153 in fiscal 2025, up from $2,406,649 in fiscal 2024.
FY2025: salary $596,667 · bonus $0 · stock awards $0 · option awards $8,405,486
Order AVBP
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Zhengbin (Bing) Yao | $596,667 | $0 | $0 | $8,405,486 | $358,000 | $0 | $14,000 | $9,374,153 |
| Chief Executive Officer and President | ||||||||
| Stuart Lutzker | 515,779 | 0 | 0 | 2,654,364 | 247,574 | 0 | 14,000 | 3,431,717 |
| President, Research and Development | ||||||||
| Winston Kung | 492,417 | 0 | 0 | 2,654,364 | 246,287 | 0 | 14,000 | 3,407,068 |
| Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Zhengbin (Bing) Yao | $9,374,153 | $2,406,649 | — | ↑ +6,967,504 |
| Stuart Lutzker | 3,431,717 | 985,967 | — | ↑ +2,445,750 |
| Winston Kung | 3,407,068 | 1,832,573 | — | ↑ +1,574,495 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Stuart Lutzker | Option | 2,820 | 2.28 | — |
| Zhengbin (Bing) Yao | Option | 10,217 | 2.28 | — |
| Stuart Lutzker | Option | 12,460 | 3.65 | — |
| Stuart Lutzker | Option | 25,680 | 7.76 | — |
| Zhengbin (Bing) Yao | Option | 41,224 | 3.65 | — |
| Winston Kung | Option | 102,726 | 7.76 | — |
| Stuart Lutzker | Option | 120,000 | 27.56 | — |
| Winston Kung | Option | 120,000 | 27.56 | — |
| Zhengbin (Bing) Yao | Option | 137,798 | 7.76 | — |
| Zhengbin (Bing) Yao | Option | 380,000 | 27.56 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Merdad Parsey, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance | $39,375 | $0 | $469,744 | — | — | $509,119 |
| John Hohneker, M.DIndependent · Compensation · Nominating and Corporate Governance | 58,125 | — | 298,026 | — | — | 505,006 |
| Kristine PetersonIndependent · Lead Independent Director · Audit · Compensation (Chair) · Nominating and Corporate Governance | 86,250 | — | 298,026 | — | — | 395,820 |
| Chris W. NoletIndependent · Audit · Nominating and Corporate Governance | 68,750 | — | 298,026 | — | — | 343,525 |
| James Healy, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance | 0 | — | 0 | — | — | 0 |
| Carl L. Gordon, Ph.D., CFAIndependent · Not standing for re-election · Departed during FY | 0 | — | 0 | — | — | 0 |
| Stuart Lutzker, M.D., Ph.DEmployee director · Nominating and Corporate Governance | — | — | — | — | — | 0 |
| Zhengbin (Bing) Yao, Ph.DEmployee director · Board Chair · Nominating and Corporate Governance | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $235,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $252,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $252,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names ArriVent BioPharma as a peer
Companies that benchmark against AVBP
No companies currently name AVBP as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | ArriVent BioPharma, Inc. | 2025 | Zhengbin (Bing) Yao | $596,667 | $0 | $8,405,486 | $358,000 | $9,374,153 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (14 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Zhengbin (Bing) Yao. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 9,374,153. View filing ↗
- Section 01, Stuart Lutzker. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 3,431,717. View filing ↗
- Section 01, Winston Kung. DEF 14A, filed 2026-04-28. Section “Executive Compensation”. As printed: 3,407,068. View filing ↗
- Section 08, Merdad Parsey, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 509,119. View filing ↗
- Section 08, John Hohneker, M.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 505,006. View filing ↗
- Section 08, Kristine Peterson. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 395,820. View filing ↗
- Section 08, Chris W. Nolet. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 343,525. View filing ↗
- Section 08, James Healy, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Carl L. Gordon, Ph.D., CFA. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Stuart Lutzker, M.D., Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Zhengbin (Bing) Yao, Ph.D. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 252,500 + equity 0 + all other 0 = 252,500, summed across the director compensation table rows.
- ArriVent BioPharma, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in ArriVent BioPharma, Inc.'s own proxy. As printed: 9,374,153. View filing ↗